Position
Forefront Analytics, LLC in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $117$771.53 → $771.80
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 427 | $329.4K | — | — | — | 0.3% |
| Q1 2026 | 460 | $355K | $771.80 | $117 | $25.5K | 0.3% |